In 2019, the first new Category 4 registered and approved respiratory preparation was launched
On April 15, 2019, Shutanlin® (Compound ipratropium bromide solution for inhalation) received the Drug Registration Approval issued by the State Food and Drug Administration. This product:
- It is the first new Category 4 registered and approved atomized solution for inhalation which is considered to have passed the consistent evaluation in China;
- As a compound preparation, it has the characteristics of synergistic effect and safe treatment;
- It is a special dosage form for aerosol treatment suitable for a wide range of people, and can reduce the risk of liquid dispensing and provide more convenient and worry-free medication options for clinic use.
[Indications]: It is suitable for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm associated with airway obstructive disease
[Administration and Dosage]: 3-4 times a day, one small vial at a time.
[Specification]: 2.5ml/vial, 10 vials/box
Official WeChat Official Account
Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved. Powered by：www.300.cn Zhuhai